Mabel Arévalo

Mabel Arévalo has extensive work experience in the field of clinical pharmacology and drug development. Mabel is currently working as the Clinical Pharmacology and Biomarkers Director at Clexio Biosciences since September 2023. Prior to this, they held roles at Oryzon Genomics SA, where they served as the Clinical Pharmacology and Drug Development Director from May 2022 to August 2023, and as the PK/PD Development Platform Leader from September 2016 to April 2022. Before joining Oryzon Genomics SA, Mabel worked at Novartis Institutes for BioMedical Research as a Laboratory Head specializing in DMPK/NPKPD from November 2013 to October 2016. Mabel also gained experience as a Study Director and Head of Department for Pharmacokinetics and ADME at Harlan Laboratories, Inc. from November 2009 to October 2013. Mabel started their career as a Postdoctoral Researcher in Molecular and Cell Biology at PRBB (Barcelona Biomedical Research Park) from November 2008 to November 2009 and as a Predoctoral Researcher in Biomedicine at IRB Barcelona from April 2003 to October 2008.

Mabel Arévalo holds a PhD in Biomedicine from IRB Barcelona, completed from 2003 to 2008. Prior to that, they pursued a Master's in Experimental Pharmaceutical Sciences, Physiology and Pharmacokinetics at the Universitat de Barcelona from 2002 to 2003. Mabel also earned a Bachelor's degree in Biology and Biomedical Sciences from the same university from 1997 to 2002. Additionally, Mabel Arévalo attended the PKPD Gabrielsson course, although the specific dates and degrees obtained are not provided.